Cargando…
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?
Targeted therapeutics underwent a revolution with the entry of monoclonal antibodies in the medical toolkit. Oligonucleotide aptamers form another family of target agents that have been lagging behind in reaching the clinical arena in spite of their potential clinical translation. Some of the reason...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Gene & Cell Therapy
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321788/ https://www.ncbi.nlm.nih.gov/pubmed/32585627 http://dx.doi.org/10.1016/j.omtn.2020.05.025 |